Abstract
The moral justification of intellectual property is often called into question when placed in the context of pharmaceutical patents and global health concerns. The theoretical accounts of both John Rawls and Robert Nozick provide an excellent ethical framework from which such questions can be clarified. While Nozick upholds an individual’s right to intellectual property, based upon its conformation with Lockean notions of property and Nozick’s ideas of just acquisition and transfer, Rawls emphasizes the importance of basic liberties, such as an individual’s right to health, superceding such secondary rights as intellectual property rights. From a policy perspective, patent protection for pharmaceutical products necessarily entails the balancing of corporate intellectual property interests and public interests in healthcare. The moral dilemma that occurs when these two interests clash is not easily resolved. Aside from corporate and public interests, the state maintains an interest in creating and preserving policies that regulate the moral dilemma itself. This paper analyzes the economic and ethical factors surrounding the production and distribution of the anti-HIV medication, AZT. Potential policy implications and recommendations are also discussed.
Similar content being viewed by others
References
J. Acanfora (1997) Royalty Distribution Formulas of Other Universities University of California UC Berkeley
J. P. Barlow (1994) ArticleTitle‘The Economy of Ideas’ Wired 2 IssueID3 1–13
J. Barton (2002) ArticleTitle‘Research-Tool Patents: Issues of Health in the Developing World’ Bulletin of the World Health Organization 80 121–125
D. W. Brock (2002) ArticleTitle‘Some Questions about the Moral Responsibilities of Drug Companies in Developing Countries’ Developing World Bioethics 1 IssueID1 33–37
P. Drahos (1996) A Philosophy of Intellectual Property Dartmouth Publishing Company Vermont 16–68
K. Freedberg E. Losina M. Weinstein (2001) ArticleTitle‘The Cost-Effectiveness of Combination Antiretroviral Therapy for HIV Disease’ New England Journal of Medicine 344 824–831
A. H. Goldman (1989) ‘Ethical Issues in Proprietary Restrictions on Research Results’ V. Weil J. W. Snapper (Eds) Owning Scientific and Technical Information: Value and Ethical Issues Rutgers University Press NJ 69–83
Haigler, T. E.: 1989, ‘Letter to the Editor’, The New York Times (16 September, Section 1), 26.
E. Hettinger (1989) ArticleTitle‘Justifying Intellectual Property’ Philosophy and Public Affairs 18 31–52
Hilts, P. J.: 1989, ‘AIDS Drug’s Maker Cuts Price by 20%’, The New York Times (18 September).
Hink, R.: 2003, ‘Intellectual Property and AIDS Medication in South Africa’, Trade and Economic Database (AIDSTRIPS, American University, DC), pp. 1--12.
M. S. Hirsch (1988) ArticleTitle‘Antiviral Drug Development for the Treatment of Human Immunodeficiency Virus Infections: An Overview’ American Journal of Medicine 85 IssueID2A 182–185
Kymlicka, W.: 2002, Contemporary Political Philosophy (Oxford University Press).
P. Laslett J. S. Fishkin (Eds) (1992) Justice Between Age Groups and Generations Yale University Press New Haven
Lindsey, D.: 2001, ‘The AIDS-Drug Warrior’, Salon Magazine (18 June), 1--5.
J. Locke (1690) NoChapterTitle P. Laslett (Eds) Two Treatises of Government. Cambridge University Press Cambridge
E. Mansfield (1993) ‘Unauthorized use of Intellectual Property: Effects on Investment, Technology Transfer, and Innovation’ M. B. Wallerstein M. E. Mooge R. A. Schoen (Eds) Global Dimensions of Intellectual Property Rights in Science and Technology Washington D.C. National Academy Press
Macron, D.: 2002, ‘AIDS Group Asks Court to Stop AZT Patent Defense’, Reuters (19 December).
H. Mitsuya K. J. Weinhold P. A. Furman et al. (1985) ArticleTitle‘3-Azido-3’deoxythymidine’ (BS A509U) Proceedings of the National Academy of Sciences U.S.A 82 7096–7100
Mitsuya, H. et al.: 1989, ‘Government Role in Development of AZT’, Letter to the Editor New York Times (28 September).
T. Moe (1984) ArticleTitle‘The New Economics of Organization’ American Journal of Political Science 28 739–777
Morel, C.: 2003, ‘Neglected Diseases: Under-Funded Research and Inadequate Health Interventions’, EMBO Reports, 4.
G. Mutume (2001) ArticleTitle‘Health and Intellectual Property Poor Nations and Drug Firms Tussle over WTO patent provisions’ Africa Recover 15 IssueID1 14–15
R. Nozick (1974) Anarchy, State, and Utopia Basic Books Inc., Cambridge, Mass
Peltz, J. F.: 1995, ‘1995–96 Review and Outlook: Top 10 Business Stories of 1995’, Los Angeles Times (31 December 1995).
W. Prosser (1971) Handbook of the Law of Torts West Publishing Co. St. Paul, Minnesota
J. Rawls (1971) A Theory of Justice Harvard University Press Cambridge, Mass
J. H. Reichman P. F. Uhlir (2003) ArticleTitle‘Contractually Reconstructed Research Commons for Scientific: Data in a Highly Protectionist Intellectual Property␣Environment’ Law and Contemporary Problems 66 315
S. K. Sell (2001) ArticleTitle‘Intellectual Property Protection and Antitrust in the Developing World: Crisis, Coercion and Choice’ International Organization 49 IssueID2 315–349 Occurrence Handle10.1017/S0020818300028411
Swarns, R.: 2001,‘Drug Firms Drop South African Drug Case’, New York Times 19 (section A), 1.
Tully, J.: 1980, A Discourse on Property (Cambridge University Press).
M. Walker (1997) ArticleTitle‘HIV, AZT, Big Science & Clinical Failure, AZT: An Aids Defining Drug part 1’ Continuum Magazine 4 IssueID6 32–36
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Amado, R., Gewertz, N.M. Intellectual Property and the Pharmaceutical Industry: A Moral Crossroads Between Health and Property. J Bus Ethics 55, 295–308 (2004). https://doi.org/10.1007/s10551-004-0993-z
Issue Date:
DOI: https://doi.org/10.1007/s10551-004-0993-z